Search Results 721-730 of 938 for alopecia

  1. A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Note: except Neuropathy Grade ≤ 2, any grade alopecia, or bone marrow parameters [any of Grade 1 or 2 permitted if directly related to bone marrow involvement] ...

  2. Chiari malformation - Diagnosis and treatment - Mayo Clinic

    To diagnose Chiari malformation, your health care professional reviews your medical history and symptoms and does a physical exam. Imaging tests can help ...

  3. Risedronate (oral route) - Side effects & dosage - Mayo Clinic

    Risedronate delayed-release tablets and tablets are used to prevent and treat osteoporosis (thinning of the bone) in women after menopause. Risedronate tablets ...

  4. Loss of smell (anosmia) Causes - Mayo Clinic

    A stuffy nose is one cause of this symptom. Learn about other causes and when it might be serious.

  5. Publications - Afsaneh Alavi, M.D. - Mayo Clinic

    Scarring hidradenitis suppurativa with phrynoderma-like eruption, alopecia, and elevated interleukin 18. JAAD Case Rep. 2025 Jan; 55:116-120 Epub 2024 Nov ...

  6. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic

    ... alopecia (Grade 2 or 3 toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for > 6 months] ...

  7. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS - Mayo Clinic

    Note: Stable chronic and clinically nonsignificant conditions (≤ Grade 2) that are not expected to resolve (eg, neuropathy, myalgia, alopecia, prior ...

  8. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    Persistence of AEs from prior anti-cancer therapy that have not resolved to Grade 1 (except for alopecia and hypothyroidism), or any history of Grade ≥ 3 ...

  9. ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer - Mayo Clinic

    03 (except alopecia or peripheral neuropathy that may be Grade 2 or less) at the time of randomization. Patients with Grade 2 neuropathy are eligible but ...

  10. Belatacept (intravenous route) - Side effects & uses - Mayo Clinic

    It is used together with other medicines to prevent the body from rejecting a transplanted kidney. When a patient receives a kidney transplant, the body's white ...